MISSOULA, Mont., March 29, 2023 /PRNewswire/ — Inimmune, a leading biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., and its Chief Operating Officer, David Burkhart, Ph.D., will play key roles at the World Vaccine Congress event.
Bioscience research and development can unlock the economic potential of the Mountain West, providing jobs and substantial economic benefit. Read how Inimmune Corporation in Missoula, Montana is bridging academic research and commercial development with the Center for Translational Medicine at the University of Montana.
To passing eyes, the town of Puyallup where Tomi Cook spent her high school years looks the perfect picture of Seattle suburbia. Quiet cookie-cutter houses, rows of shopping centers, happy upper-middle-class families going about their happy lives. She doubts anyone would have suspected that pills were tearing through her community. For Cook it started with […]
Inimmune Corporation is joining in on efforts to develop a COVID-19 vaccine with a nasal spray that could offer protection against coronavirus. The research efforts are in collaboration with the University of Montana’s Center for Translational Medicine and Rocky Mountain Laboratories in Hamilton.
Montana Biotech Company Receives $2 M Small Business Innovation Research Grant to Advance Vaccine Technologies
Inimmune Corporation, a biotechnology company located in Missoula, MT, was recently awarded a $2 M grant from the National Institute for Allergy and Infectious Diseases (NIAID) under its Small Business Innovation Research (SBIR) Direct to Phase II program to advance a novel adjuvant and delivery system for vaccines. Adjuvants are vaccine components that stimulate and […]
Inimmune, a Missoula-based biotech company founded by nationally recognized vaccine scientists that has been working on a vaccine for COVID-19, announced today that it has raised $22 million in Series A funding led by Two Bear Capital, a venture-capital firm founded by Whitefish philanthropist Mike Goguen. The firm plans to use the Series A investment […]
(Missoula, MT) Inimmune, www.inimmune.com, a biotechnology company developing immune therapies and components for more effective vaccines, announced today that it raised $22 million in Series A funding. It was the Missoula-based company’s first outside investment. The round was led by Two Bear Capital, www.twobearcapital.com, a new firm based in Whitefish, Montana. Two Bear Capital Founder and Managing Partner Michael […]
MISSOULA – The National Institutes of Health has awarded the University of Montana a five-year, $33.4 million award for the development and clinical trials of opioid vaccines. It is the largest such award in University history. The award was funded through the NIH HEAL Initiative, a national effort to speed scientific solutions to the national opioid […]
LAKE HAVASU CITY, Ariz. — Many anglers like to escape to the water, leaving the cares of the world back on land. Jay Evans is certainly one of them, but he knows that a day of fishing always is followed by a hard day of work, and it’s not necessarily work he can wait a […]
For Missoula’s Inimmune, a $22 M Series A Round with Two Bear Capital is the latest record set – MT High Tech Business Alliance
In July 2020, Missoula-based biotech therapeutics company Inimmune Corporation announced the largest Series A investment in Montana history: a $22 million round led by Two Bear Capital out of Whitefish. Founded in 2016, Inimmune develops vaccines and immunotherapeutics in allergy, autoimmunity, infectious disease, opioid addiction and cancer with multiple candidates rapidly advancing to Phase I […]